B Bertisch
Trends in hepatitis C-related mortality in Switzerland
Keiser O, Spoerri A, Negro F, Estill J, Bertisch B, Brezzi M, Semela D, Terziroli B, Bruggmann P, Moradpour D, Dufour J, Junker C, Mullhaupt B, Giudici F, Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat 2017; 25:152-160.
20.11.2017Trends in hepatitis C-related mortality in Switzerland
20.11.2017J Viral Hepat 2017; 25:152-160
Keiser O, Spoerri A, Negro F, Estill J, Bertisch B, Brezzi M, Semela David, Terziroli B, Bruggmann P, Moradpour D, Dufour J-F, Junker C, Mullhaupt B, Giudici F, Swiss Hepatitis C Cohort Study and the Swiss National Cohort
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-9.
01.02.2005Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
01.02.2005Infection 2005; 33:25-9
Huber M, Weber R, Oppliger R, Vernazza Pietro, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E L